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ABSTRACT 
Cells are constantly exposed to DNA damaging insults. To protect the organism, 
cells developed a complex molecular response coordinated by P53, the master 
regulator of DNA repair, cell division and cell fate. DNA damage accumulation and 
abnormal cell fate decision may represent a pathomechanism shared by aging-
associated disorders such as cancer and neurodegeneration. Here, we examined 
this hypothesis in the context of tauopathies, a neurodegenerative disorder group 
characterized by Tau protein deposition. For this, the response to an acute DNA 
damage was studied in neuroblastoma cells with depleted Tau, as a model of loss-of-
function. Under these conditions, altered P53 stability and activity result in reduced 
cell death and increased cell senescence. This newly discovered function of Tau 
involves abnormal modification of P53 and its E3 ubiquitin ligase MDM2. Considering 
the medical need with vast social implications caused by neurodegeneration and 
cancer, our study may reform our approach to disease-modifying therapies. 
 
INTRODUCTION 
Tauopathies are disorders of Tau protein deposition best represented by 
Alzheimer’s disease (AD), where Tau accumulation in neurofibrillary tangles of the 
brain correlates with the clinical course in terms of number and distribution1, 2. Also, 
mutations in the MAPT gene encoding for Tau lead to frontotemporal dementia with 
Parkinsonism 171, 2. Since Tau is a microtubule-associated protein, an accepted 
concept explaining the pathogenesis of tauopathies is that abnormal phosphorylation 
and folding cause Tau detachment from microtubules, Tau accumulation, and 
neuronal dysfunction3, 4. In addition to microtubule association, Tau localizes in the 
cell nucleus and binds DNA5-8 and also forms a complex together with P53, Pin1 and 
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PARN regulating mRNA stability through polyadenylation9. Nuclear Tau was shown 
to have a role in DNA protection, whereby heat or oxidative stress cause nuclear Tau 
translocation10. Enhanced DNA damage was observed in Tau-KO neurons when 
compared to normal neurons11. We reported that drug-induced DNA damage also 
causes Tau nuclear translocation and affects Tau phosphorylation12. Notably, 
checkpoint kinases controlling DNA replication and cell cycle following a DNA 
damage phosphorylate Tau13. Together with chromosomal abnormalities found in 
AD-derived fibroblasts14 and increased DNA damage in AD brains15, 16, the emerging 
function of Tau in DNA stability offers an alternative role of Tau in neurodegeneration 
and, importantly and insufficiently investigated, also in the DNA damage response 
(DDR). DNA is continuously damaged by genotoxic agents originating from the 
environment or generated intracellularly. The integrity of the genome is ensured by 
an efficient DDR signaling network regulating cell cycle and the DNA repair 
machinery, but also the activation of cell death or senescence when DNA damage 
persists. DDR deregulation causes accumulation of DNA errors and genomic 
instability, both implicated in age-related pathologies as cancer and 
neurodegenerative disorders17.  
In order to evaluate a role of Tau in this process, we depleted Tau in human cells 
and then carefully analyzed the DDR. We demonstrate that Tau deficiency renders 
cells less sensitive to DNA damage-induced apoptosis, which is counterbalanced by 
increased senescence. We show that this activity of Tau is mediated through a P53 
modulation. Overall, our findings propose a role of P53 in tauopathies and a role of 
Tau in P53 dysregulation, a key event in oncogenesis. 
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RESULTS 
Generation and characterization of Tau-KO and Tau-KD cells  
We opted the use of human SH-SY5Y neuroblastoma cells for generating Tau 
knock-out (Tau-KO) cells by the CRISPR-Cas9 technology and Tau knock-down 
(Tau-KD) cells by shRNA interference (Fig.1). For disruption of the MAPT gene, we 
designed gRNAs targeting Cas9 endonuclease to two sequences in the first coding 
MAPT exon. CRISPR-Cas9 cell lines were screened for Tau expression by 
fluorescent confocal microscopy and immune protein blotting with the human-specific 
N-terminal Tau13 antibody. So, we identified cell lines devoid of Tau (Fig.1a and 
Supplementary Fig.7a). Since the Tau13 epitope is within the Cas9-targeted exon, 
false negatives may perhaps result from in-frame indels or abnormal mRNA 
processing. With the HT7 antibody against amino acid 159-164 of Tau441, we 
confirmed the isolation of Tau-KO lines lacking full-length or truncated Tau 
expression (Fig.1a and Supplementary Fig.7a). We finally selected the cell lines 
232P and 231K presenting alleles modified at the expected gRNA-sites by indels 
causing frame-shifts into stop codons within the same exon (Fig.1a). The 231A cell 
line underwent an unsuccessful CRISPR-Cas9 procedure and had normal Tau 
expression (Fig.1a). 
To obtain Tau-KD cells, we screened shRNAs targeting the coding sequence or 
the 3’ untranslated region of the Tau mRNA. Culturing shRNA transduced cells in the 
presence of puromycin resulted in the isolation of cell populations with constitutive 
down-regulation of Tau for three shRNAs as shown by immune staining and western 
blot (Fig.1b and Supplementary Fig.7b).  
Tau deficiency protects against DNA damage-induced apoptosis  
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Persistent DNA damage induces cell death or senescence. Thus, as a functional 
readout for the DDR, we assessed the cytotoxicity following a mild exposure to 
etoposide18, a DNA topoisomerase II inhibitor causing double-stranded DNA breaks 
(DSBs). Cell viability was first tested with the well-established LDH and the MTS 
assays. Tau-KO cells exposed to a short (30 min) 60 µM etoposide treatment did not 
release LDH in the culture medium and more efficiently converted MTS when 
compared to Tau-expressing cells, which exhibited substantial etoposide-dependent 
cytotoxicity in both assay (Fig.2). To test the involvement of apoptosis, we immune 
stained cells for cleaved active caspase-3 (clCasp3), an initiator of apoptosis. Whilst 
<1% of the untreated Tau-expressing cells were positive for clCasp3, etoposide 
exposure increased the apoptotic population to 13-15%, apoptosis was induced in 
only 4-5% of Tau-KO cells (Fig.2). The presence of activated clCasp3 in Tau-
expressing cells exposed to etoposide and its almost complete absence in Tau-KO 
cells was confirmed by western blot analysis with the same antibody for the cleaved 
enzyme form (Fig.2 and Supplementary Fig.8). As a whole, we found a positive 
association between Tau expression and DSB-induced apoptosis in SH-SY5Y cells. 
Tau depletion induces cellular senescence  
In alternative to cell death, unresolved DNA damage may provoke cellular 
senescence17. Inhibition of cyclin-dependent kinase by p21 causes cell cycle arrest 
and induction of senescence19, 20. When compared to untreated conditions, at three 
recovery days after etoposide exposure (Fig.3a), higher amounts of p21 were 
detected by western blot in both Tau-expressing and Tau-KO cells (Fig.3b). When 
comparing the extent of this effect in the absence or the presence of Tau, we found 
that Tau depletion increased p21 both at basal conditions as well as after etoposide 
treatment when compared to wt cells (Fig.3b). The increased amount of p21 present 
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in Tau-KO cells suggests that Tau-depletion may prone cells to enter a senescence 
state further accelerated in the presence of DSBs. We determined the number of 
cells entering in a senescent state based on their mean cell size and by the 
senescence-associated β-galactosidase (SA-βGal) staining procedure at mild acidic 
conditions. When compared to untreated conditions, significantly increased cell size 
and SA-βGal-positive cells were found at three recovery days after etoposide 
exposure both for wt and Tau-KO cells (Fig.3b). Again, Tau-depleted cells at basal 
conditions displayed a larger proportion of senescent cells in terms of cell size, SA-
βGal staining and p21 expression (Fig.3b). A consistent observation was made also 
for Tau-KD cells when compared to control shRNA cells (Fig.3c and d). We 
concluded that reduced expression of endogenous Tau changed the fate of SH-
SY5Y cells as a consequence of DSBs, favoring cellular senescence induction at the 
expense of activation of programmed cell death. 
DNA damage and DDR activation are not reduced  
DSBs lead to rapid recruitment and phosphorylation of the H2A histone family 
member at the site of DNA damage, and so the presence of H2A-X is utilized as a 
surrogate marker of DNA damage. We first performed an accurate etoposide dose-
response by in-cell western for H2A-X staining normalized by nuclear DAPI staining 
and observed an increase detection of H2A-X total staining in Tau-KO cells when 
compared to control cells (Fig.4a). The Comet assays is a direct measure of the 
magnitude of DSBs in single cultured cells. No difference between control and Tau-
KO cells was found at the end of the etoposide treatment or during the recovery, 
which was rapid and complete before the 6 h washout time point independently on 
the presence or absence of Tau. However, Tau deletion led to more DSBs at basal 
conditions (Fig. 4b). Our data were thus consistent with a role of Tau in DNA-
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protection10, 11. In contrast, the relatively small increase in etoposide-mediated DNA 
damage in Tau-KO cells inadequately explained reduced DNA damage-induced cell 
death in Tau-depleted cells. To corroborate this observation, we performed an 
etoposide dose-response and determined by confocal microscopy the presence of 
immune-stained nuclear H2A-X and of the DSB-activated forms of ATM and Chk221, 
22. This demonstrated a robust and dose-dependent induction of all three markers at 
30 min after etoposide treatment (Fig.4c). The difference between wt and Tau-KO 
cells was relatively minor and suggested a slightly stronger activation of the early 
DDR in Tau-KO cells, although the results obtained at 0 h and 6 h recovery were less 
conclusive (Fig.4d). Overall, the modest and somehow opposite effect of Tau 
depletion on the early DDR when compared to cell death induction, suggested a 
downstream contribution of Tau in modulating cell death.  
Tau modulates DDR-dependent stabilization of P53 protein  
A key DDR regulator is the tumor suppressor protein P53, which first halts cell 
division and then dictates cell fate when DNA damage persists23, 24. To check the 
requirement of P53 for apoptosis induction in our cell model, we transduced cells with 
viral pseudoparticles and isolated stable P53 shRNA expressing cells 
(Supplementary Fig.1a). The effect of the shRNA was negligible at basal conditions, 
i.e. when the cells maintain a minimal amount of P53 due to its efficient degradation. 
In contrast, P53-KD cells displayed reduced etoposide-dependent P53 stabilization 
when compared to control cells as demonstrated by western blot analysis with the 
monoclonal antibodies DO-1 and Pab 1801 and confirmed by immune staining with 
DO-1 (Supplementary Fig.1b and c). Cell lysates obtained from the neuroblastoma 
cell line SK-N-AS carrying a homozygous deletion in the TP53 gene and therefore 
not expressing P5325, were used as a negative control for P53 immune detection. 
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Etoposide treatment induced apoptosis in ~2% P53-KD cells compared to ~14% of 
the control cells (Supplementary Fig.1d). These data confirmed the involvement of 
P53 in DSB-induced apoptosis also in SH-SY5Y cells.  
Having exposed the contribution of P53 and Tau in modulating DNA damage-
dependent apoptosis in SH-SY5Y cells, we next asked whether Tau may modulate 
P53 activation. Tau-KO cells presented reduced DNA damage-induced nuclear P53 
when compared to Tau-expressing cells as shown by immune staining and western 
blot (Fig.5a and Supplementary Fig.2a and b). Reduced P53 was observed when 
Tau-KO cells were exposed to 30, 60 or 90 µM etoposide and let recover for 30 min 
or 6 h (Fig.5a). Reduced etoposide-induced apoptosis in Tau-KO cells displayed a 
similar dose-dependent effect (Fig.5b).  
Further documenting the role of Tau in etoposide-induced cytotoxicity, re-
expressing high levels of human Tau441 in Tau-KO cells (Supplementary Fig.3a, 
Supplementary Fig.11) increased P53 stabilization in etoposide treated cells 
(Supplementary Fig.3b) and restored sensitivity in the LDH and clCasp3 assays 
(Supplementary Fig.3c). In order to obtain, reconstituted Tau expression at a level 
similar to that of endogenous Tau, in a second set of experiments Tau-KO cells were 
transiently transfected with a 1:10 mixture of Tau410 and GFP plasmids or of empty 
and GFP plasmids. Tau expression was then analyzed in GFP-positive cells co-
transfected either with the Tau410 or the empty plasmid by immune staining. This led 
to determine a level of ectopic expression corresponding to ~2-fold that of 
endogenous Tau determined in parental SH-SY5Y cells (Supplementary Fig.3d). 
Under these conditions, 6 h after etoposide exposure Tau410-transfected Tau-KO 
cells displayed increased P53 stabilization when compared to that detected in empty 
plasmid-transfected Tau-KO cells (Supplementary Fig.3e). 
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Tau-KD-cells with reduced Tau-expression corresponding to 71 ± 1% for the 3127 
shRNA and 64 ± 2% for the 2112 shRNA (Fig.5c) when exposed to etoposide also 
showed reduced P53 activation (Fig.5d) and apoptosis (Fig.5e) in a Tau-dose 
dependent manner. On the other hand, 60 ± 1% reduced Tau in 1881 shRNA cells 
did not affect P53 protein level and apoptosis (Fig.5c to e). Single cell analysis of the 
whole Tau-KO or Tau-KD cell population revealed that when we applied a threshold 
just above background to count P53-positive cells, etoposide-dependent P53 
stabilization was better described by a change in the relative number of P53 positive 
cells rather than by a gradual correlation between Tau and P53 expression (Fig.5f).  
Reduced P53 and apoptosis occurs in other neuroblastomas  
In order to validate the observation made in SH-SY5Y cells, we tested the effect of 
Tau down-regulation in IMR5 and IMR32 human neuroblastoma cell lines. Similar to 
SH-SY5Y cells, these two cell lines express a wild-type functional P5326, 27. Several 
other neuroblastoma cell lines were disregarded because P53 mutations were 
causing either constitutive activation or expression loss of P5327. Tau expression in 
IMR5 cells was down-regulated ~4-fold in the presence of the 2112 shRNA 
(Supplementary Fig.4a). Under these conditions, we observed lower etoposide-
induced P53 stabilization in Tau-KD when compared to mock-transduced IMR5 cells 
as determined by western blot and immune staining analysis (Supplementary Fig.4b). 
Similar to what observed in SH-SY5Y cells, etoposide-induced clCasp3 was also 
reduced in Tau-depleted IMR5 cells (Supplementary Fig.4c). The presence of the 
3127 shRNA in IMR32 cells lowered Tau expression by ~40%, which resulted in 
reduced P53 stabilization and caspase-3 activation in cells exposed to the etoposide 
treatment (Supplementary Fig.4d-f). 
Tau regulates P53 expression post-translationally 
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To assess whether lower P53 protein level observed in Tau-KO cells was 
occurring by transcriptional or post-translational mechanism, we first determined by 
quantitative RT-PCR the amount of the P53 mRNA in wt and Tau-KO cells before or 
6 h after the acute etoposide treatment. At basal conditions Tau-KO and Tau-KD 
cells showed a significant but modest increase in TP53 transcription when compared 
to Tau-expressing cells. Etoposide exposure slightly increased the P53 transcript in 
all cell lines, but there was no difference when comparing treated Tau-expressing 
and treated Tau-KO cells (Fig.6a and b). Overall, these data essentially dismissed 
the premise that the effect of Tau depletion on P53 stabilization occurred at the 
transcriptional level, rather suggesting a translational or post-translational control. On 
the other hand, etoposide treatment resulted in the expected P53-dependent 
upregulation of HDM2 transcription, but this was markedly reduced in Tau-KO and in 
Tau-KD cells (Fig.6a and b), a result that was confirmed also at the MDM2 protein 
level (Supplementary Fig.5). Analysis of additional direct targets of P5328, 29 showed 
a differential transcriptional response to etoposide in Tau-depleted cells. Whilst, 
transcription of the EI24 gene was reduced in etoposide-treated Tau-KO cells, that of 
RRM2B, TNFRSF10B, DDB2, ZMAT3, ASCC3 and CDKN1A was not affected in 
Tau-KO cells (Fig.6a). Dysregulation of transcription of the P53 targets was more 
evident in Tau-KD cells, which showed reduced etoposide-induction for the MDM2, 
DDB2, RRM2B, ZMAT3, ASCC3 transcripts, and no effect on the EI24 and 
TNFRSF10B transcripts (Fig.6b). Interestingly, as observed for the CDKN1A protein 
product p21 (Fig.3c), also the CDKN1A transcript was increased in Tau-KD cells after 
etoposide treatment (Fig.6b), whereas this did not reach significance in Tau-KO cells 
(Fig.6a). A different regulation of direct P53-dependent genes after etoposide 
exposure, conveyed by a positive or negative difference in the degree of transcription 
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activation between cells with normal or reduced Tau expression, substantiated a 
Tau-dependent modulation of P53 function at a post-translational level. Also, the 
heterogeneous response observed among the different P53 targets cannot be 
explained solely by a change in P53 protein stability but implied a more complex 
modulation of P53 activity. 
Tau affects P53 and MDM2 modification 
A post-translational clearance mechanism keeps P53 protein at low levels in the 
absence of a cellular stress30. This occurs mainly, but not exclusively, by the activity 
of the E3 ubiquitin ligase MDM2 (also known as HDM2) that associates with P53 to 
favor its degradation and interfere with its function30,31. We determined the amount of 
nuclear MDM2 and found that induction of MDM2 was lower in Tau-KO cells when 
compared to Tau-expressing cells, possibly explained by reduced gene transcription 
(see above, Fig.6), whereas MDM2 expression in untreated cells was not modulated 
by Tau (Supplementary Fig.5). Post-translational modification of P53 through the 
action of DDR transducing kinases causes the dissociation of the P53-MDM2 
complex and induces stress-dependent P53 stabilization. In the presence of DSBs, 
this occurs mainly by N-terminal phosphorylation of the P53 transcription-activation 
domain by the ATM-Chk2 axis22. We tested two small molecules interfering with this 
process. KU-55933 is an ATM inhibitor blocking ATM-dependent P53 
phosphorylation thus preserving the P53-MDM2 complex and its degradation. Nutlin-
3 binds to the P53-binding pocket of MDM2 thus inhibiting their association and 
degradation. KU-55933 had no effect on P53 and MDM2 expression when tested 
alone (Fig.7a). As expected, adding the drug after etoposide treatment severely 
impaired DSB-induced P53 and MDM2 stabilization and also blocked apoptosis 
activation (Fig.7a and b). Consistent with its mode of action, the presence of nutlin-3 
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led to a strong increase in P53 and MDM2, which was higher to that caused by 
etoposide but, notably, did not induce apoptosis (Fig.7a and b). Nutlin-3 potentiated 
the effect of etoposide in terms of P53-MDM2 stabilization in wt cells. In Tau-KO cells 
exposed to etoposide, nutlin-3 eliminated the drop in MDM2 and partly also that in 
P53 (Fig.7a and b). Determination of P53 phosphorylation at S15 when normalized for 
total P53 protein showed a similar etoposide-dependent relative occupancy in Tau-
KO cells when compared to Tau-expressing cells (Supplementary Fig.6a). This was 
an unexpected result because amino-terminal P53 phosphorylation should stabilize 
P53 by interfering with the binding to MDM2, and thus increased P53 destabilization 
in Tau-KO cells should be reflected by a reduction in P53 phosphorylation. A possible 
explanation is that reduced DSB-dependent stabilization of P53 caused by the 
absence of Tau might be compensated by a change in P53 phosphorylation. 
Etoposide-induced P53 phosphorylation at S15 was severely impaired by the ATM 
inhibitor KU-55933 (Supplementary Fig.6b), but this only partially blocked apoptosis 
induction in wt cells and had no effect in Tau-KO cells when compared to etoposide-
exposure alone (Fig.7b). In addition, P53 stabilization by nutlin-3 did not involve S15 
phosphorylation (Supplementary Fig.6b) and poorly induced apoptosis (Fig.7b). Our 
attempts to analyze pS46-P53 phosphorylation was unsuccessful as no signal was 
detected also under conditions of prolonged etoposide treatment both in Tau-
expressing and Tau-KO cells. We concluded that in SH-SY5Y cells, DSB-induced 
apoptosis was at least in part dependent on P53 modification. 
Tau-depletion increases P53 degradation rate 
To address if Tau-KO cells displayed faster P53 degradation possibly accounting 
for the lower detection of P53 protein, we first inhibited the ubiquitin-proteasome 
system by treating the cells with MG132. The presence of MG132 during the 
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recovery phase from etoposide exposure restored P53 stabilization in Tau-KO cells 
but had no effect in wt cells, suggesting that the absence of Tau favored P53 
degradation (Fig. 7c and Supplementary Fig.9c).  
Taking advantage of the fact that MG132 was able to restore similar P53 protein 
levels in wt and Tau-KO cells exposed to etoposide, we then analyzed the rate of 
degradation of P53 and MDM2 by removing MG132 and adding the translation 
inhibitor cycloheximide. Under these conditions we observed a faster P53 
degradation rate at 2 and 4 h wash-out in Tau-KO cells when compared to wt cells 
(Fig.7d). In contrast, no difference was observed in terms of MDM2 degradation 
(Fig.7d).  
Western blot analysis of MDM2 with the same rabbit antibody used for immune 
staining of the cells confirmed reduced MDM2 expression in Tau-KO cells exposed to 
etoposide when compared to wt cells (Fig.7e and Supplementary Fig.9e). 
Interestingly, when using a mouse antibody for MDM2, we also detected a 60 kDa 
MDM2 form (Fig.7e and Supplementary Fig.9e), likely representing the amino-
terminal caspase-2 cleavage product of full-length 90 kDa MDM232, 33. An opposite 
effect of etoposide-exposure was obtained for these two forms of MDM2 in Tau-KO 
cells when compared to wt cells. Although reduced 90 kDa MDM2 detection was 
confirmed in Tau-KO cells, in the same cells we found that etoposide markedly 
increased 60 kDa MDM2 (Fig.7e and Supplementary Fig.9e).  
Tau does not interact with P53  
In the presence of the proteasome inhibitor, the interaction between P53 and 
MDM2 was confirmed by a co-precipitation experiment both in the presence and in 
the absence of etoposide treatment (Fig.8 and Supplementary Fig.10). However, 
although etoposide increased the amount of MDM2 detected in cell lysates when 
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compared to the control, for both conditions a similar amount of MDM2 was co-
precipitated by P53; a result consistent with decreased P53-MDM2 interaction as a 
consequence of DNA damage. In contrast, we did not detect any interaction between 
P53 and Tau in the presence or absence of DNA damage (Fig.8 and Supplementary 
Fig.10), suggesting that the modulatory function of Tau on P53 stabilization may not 
occur by a direct interaction between the two proteins in SH-SY5Y cells. 
The data obtained implied that in neuroblastoma cells Tau modulated P53 in a 
manner that went beyond a simple regulation of its stabilization, but accounted also 
for a deregulation of P53 and MDM2 post-translational modification ultimately 
affecting the activity and function of P53 in cell fate decisions dependent on DNA 
damage. 
DISCUSSION 
We report a new function of Tau as a regulator of DSB-induced cell fate and 
describe that this occurred by a deregulation of P53 activity. Our data support a role 
for Tau as a P53 modifier in neurodegeneration. Uncontrolled P53 activity in the 
presence of P53 or MDM2 mutations is one of the main pathomechanism of cancer34. 
Not surprisingly, the P53-MDM2 axis includes a variety of factors regulating their 
modification and localization35. Based on our data, Tau should now be listed as a 
modifier of wild-type P53 function, with possible implications in cancer biology. 
The involvement of apoptosis in neurodegeneration is documented36, but whether 
this is modulated by Tau remains questionable37, 38. We show now that a brief DNA 
damaging insult positively associates Tau to programmed cell death and negatively 
to cellular senescence. Positive association to cell loss was already shown in 
Bloom’s syndrome cells under continuous DNA damage for three days, although a 
distinction between cell death and senescence was not clear39. Age-dependent 
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increase in senescent cells promotes tissue deterioration and neuronal dysfunction40, 
41. Moreover, increased senescent glia cells were found in a tauopathy model 
characterized by reduced soluble Tau and, remarkably, senescent cell removal 
prevented functional neuronal decline42. Nevertheless, direct evidence that Tau loss-
of-function may promote senescence was not yet reported. 
In the adult human brain, post-mitotic neurons express Tau in multiple alternative 
spliced isoforms that differ depending on the presence of up to two N-terminal inserts 
(0N, 1N, 2N) and on the presence of three or four microtubule-binding repeats (3R, 
4R). In early development, 3R-Tau isoforms are predominant whereas in the adult 
brain the 3R and 4R isoforms are detected at a similar level, although they ratio is 
substantially altered in a peculiar manner for distinct tauopathies43. The cell lines 
used in our study (SH-SY5Y, IMR-32 and its subclone IMR-5) express predominantly 
the embryonic isoform 3R-Tau when actively dividing44-46. Our results showing that 
the effect of endogenous Tau deletion was reversed by ectopic expression of either 
4R-Tau441 or 3R-Tau410 suggest that the modulatory role of Tau on P53 is possibly 
shared by all Tau isoforms. Tau phosphorylation in undifferentiated SH-SY5Y is 
increased46, so at this time we cannot exclude that the modulatory effect of Tau on 
P53 may require modification of Tau by phosphorylation. 
The balance between apoptosis and senescence is regulated by an intricate 
mechanism, which varies in response to distinct stressors47. In terms of DNA 
damage, crucial determinants are the nature and intensity of the stress. Since P53 
drives both the induction of apoptosis and senescence, cell fate is finely tuned by 
changes in P53 kinetics and transcriptional activity under post-translational 
modification control48. The inference that Tau modifies P53 protein expression and 
the balance between cell death and senescence, suggests Tau as a modifier of P53 
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post-translation modification by acting on P53 modulators. P53 is modified by most 
types of substituents, which dictate the complex response to a wide range of cellular 
conditions49. Ubiquitination and phosphorylation control P53 stability, subcellular 
localization and transcriptional versus non-transcriptional activity, as well as cellular 
senescence50 and apoptosis51. P53 acetylation may govern transcriptional-regulation 
of gene targets involved in growth arrest, and the choice to enter senescence or 
apoptosis52. In our cellular model, treatment with nutlin-3 restored P53 stabilization 
without involving P53 phosphorylation in Tau-depleted cells exposed to etoposide, 
but poorly reversed reduced activation of the apoptotic pathway. Nutlin-3 restored 
also the expression of the P53 negative regulator MDM2, which targets P53 for 
degradation, regulates its nuclear localization, and the interaction of P53 with 
transcriptional co-factors35. Therefore, considering only the protein amount of P53 or 
MDM2 inadequately explains the role of Tau as an effector balancing apoptosis and 
senescence. Additional P53-interacting protein such as WW domain-containing 
oxidoreductase (WWOX), which modulate Tau phosphorylation, may be involved in 
Tau-dependent regulation of P5353, 54.  
Tau has been described recently to be part of a complex containing P53, PARN 
and Pin1 involved in the regulation of mRNA stability through regulation of 
polyadenylation9. In this report, in HCT-116 colon cells Tau expression modulated the 
level of the P53 transcript and P53 that of Tau. In our cellular model, we also 
observed that Tau was able to modulate P53 expression, but we excluded that this 
occurred at the level of gene transcription but instead showed a post-translational 
mechanism. Nevertheless, the action of Tau on P53 degradation, on P53 activity as 
transcription factor and on P53 function as cell fate mediator reported herein for SH-
SY5Y cells may well be regulated by a Tau complex similar to that described for 
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HCT-116 cells. However, HCT116 and other colon cancer cell lines modify Tau to an 
hyperphosphorylated form resembling the one deposited in tauopathy brains55, 
suggesting a difference in function between pathogenic and physiological Tau. 
Increased DNA damage has been reported as a consequence of Tau deletion and 
heat stress, indicating a protective role of Tau against DNA damage, which may 
require nuclear Tau translocation10, 11, 35. We reported that also etoposide exposure 
increased nuclear Tau and reduced its phosphorylation12. In the present study, 
determination of DNA integrity assessed by the Comet and H2A-X assays confirmed 
the protective role of Tau, but rebuffed the possibility that decreased DNA damage in 
the absence of Tau may be the reason for decreased DSB-induced cell death. 
Moreover, we did not observe an overt effect on the ATM-Chk2 axis, implying that a 
downstream pathway was affected in Tau-KO cells.  
P53 stabilization and apoptosis induction depended on the activity of the ATM-
Chk2 axis, because they were stopped by the ATM inhibitor KU-55933. An 
alternative reading is that Tau may intervene on P53 modification or on its functional 
modulators. Whether this occurs in the cytosol, possibly based on its activity on 
microtubules, or following its nuclear translocation is yet to be examined. P53 has 
been shown to associate to and be regulated by microtubules56, 57. Therefore, Tau 
may affect P53 interaction with the cytoskeleton by modulating microtubule 
dynamics. However, Tau is also present in the nucleus in normal and stress 
conditions and some functions associated to nuclear Tau were suggested10, 11, 58-60.  
The implication of the neurodegeneration-associated Tau protein in the biology of 
P53, the “guardian of the genome”, is a thrilling finding that may explain the role of 
P53 and DDR dysfunction in neurodegeneration and the link between Tau and 
cancer. Abnormal P53 species are potential biomarkers of AD61-63, the most common 
Sola et al. Tau modulates P53 and senescence  page 18 
tauopathy with an high incidence of P53 mutations64 and P53 deregulation65. Genetic 
manipulation of P53 family members in mice affects aging, cognitive decline, and Tau 
phosphorylation66, 67. Cell cycle activators are upregulated in post-mitotic neurons by 
stress conditions and tauopathies, possibly representing a cause for 
neurodegeneration68, 69. Increased DNA damage is found in AD15, 16 and persistent 
DDR causes neuronal senescence and upregulation of pro-inflammatory factors70. 
Our finding that cellular senescence is increased by DSBs in Tau-KO cells is 
consistent with these observations. 
Intriguingly, hyperphosphorylated and insoluble Tau is detected in some prostate 
cancer71, FTDP-17 MAPT mutations increase the incidence of cancer72, and higher 
levels of phosphoSer199/202-Tau have value as predictors of non-metastatic colon 
cancer73. More recently several reports described that high Tau expression improves 
survival in several types of cancers74-77. Intriguingly, Tau deficiency resulting in 
reduced P53 stabilization reported herein provides a mechanism to explain why 
reduced Tau represents a negative prognostic marker. Moreover, since our data 
show that Tau expression also modulates etoposide cytotoxicity, we would like to 
propose that Tau protein level may acquire value as a response marker of genotoxic 
therapy.  
Cancer and neurodegenerative diseases may involve common signaling pathways 
balancing cell survival and death78-80 and may be defined as diseases of 
inappropriate cell-cycle control as a consequence of accumulating DNA damage. 
Epidemiological studies show an inverse correlation between cancer and 
neurodegeneration79, although not consistently81, 82, and chemotherapy is associated 
to a lower predisposition for AD83, 84. The study of Tau as a modifier of P53 and, 
importantly, P53 control of cell death and senescence is crucial because of the 
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implication that Tau may modulate cell death and senescence in neurodegenerative 
tauopathies and in cancer. Considering the unmet medical need with vast social 
implications caused by these - unfortunately frequent - disorders, our finding holds 
sizeable scientific importance and may lead to innovative approaches for disease-
modifying therapeutic interventions. 
METHODS 
Cell Culture and DNA transfections 
Human neuroblastoma IMR5, IMR32 and SK-N-AS were kindly provided by Dr. 
Chiara Brignole and Dr. Mirco Ponzoni from the IRCCS Istituto Giannina Gaslini in 
Genova. These cells and the human neuroblastoma SH-SY5Y cells (94030304, 
Sigma-Aldrich) were cultured in complete DMEM: Dulbecco's Modified Eagle Medium 
(61965-059, Gibco) supplemented with 1% non-essential amino acids (11140035, 
Gibco), 1% penicillin-streptomycin (15140122, Gibco) and 10% fetal bovine serum 
(10270106, Gibco). Cells were grown at 37°C with saturated humidity and 5% CO2, 
and maintained in culture for <1 month. Cells grown on poly-D-lysine (P6407, Sigma-
Aldrich) were transfected with jetPRIME (114-15, Polyplus) or Lipofectamine 3000 
(L3000008, Invitrogen) according to the manufacturer’s instructions or with the 
calcium phosphate method85.  
Targeted disruption of Tau expression  
For disruption of the MAPT gene encoding for Tau by the CRISPR-Cas9 method, 
the two gRNAs 231 and 232 (Table 1) targeted exon 2 containing the initiating ATG 
(ENST00000344290.9). Cells in 6 well plates were transfected with the plasmid 
kindly provided by Dr. Zhang86 (52961, Addgene) driving expression of one of the two 
gRNA, Cas9 nuclease and puromycin resistance. One day post-transfection, cells 
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were transferred to 10 cm plates and incubated for two days with 20 µg/mL 
puromycin (P8833, Sigma-Aldrich). Single colonies were isolated, amplified, and 
stored in liquid nitrogen. The cDNA encoding for human Tau isoform of 441 amino 
acids (Tau441) in the expression plasmid pcDNA3 and selection in 0.5 mg/mL 
Geneticin (11811031, Gibco) served to generate reconstituted Tau expression in the 
Tau-KO 232P cell line.  
Sequencing of the targeted MAPT gene 
Cell pellets were resuspended in 400 μL TNES buffer (0.6% SDS, 400 mM NaCl, 
100 mM EDTA, 10 mM Tris pH 7.5) and 0.2 mg/mL proteinase-K (Abcam, ab64220) 
under continuous shaking 3-4 h at 50°C, and then supplemented with 105 μL of 6 M 
NaCl. Genomic DNA was precipitated with one volume of ice-cold 100% ethanol, 
washed with 100% ethanol and with 70% ethanol, and air-dried. The genomic 
fragment containing the CRISPR-Cas9 targeted regions was amplified by PCR with 
primers containing BamHI or XhoI restriction sites (Table 2) with the AccuPrime™ Pfx 
SuperMix (12344-040, Invitrogen). PCR reactions were purified with the GeneJET 
PCR purification kit (K0701, ThermoFisher Scientific) and subcloned in pcDNA3. 
DNA from single bacterial colonies were analyzed by restriction mapping with Ndel & 
XhoI or Van91I, in order to verify the presence and the MAPT origin of the inserts. 
Inserts with different size were selected in order to increase the chance of 
sequencing both alleles (Microsynth). 
Down-regulation of Tau or P53 expression  
Short hairpin RNAs (shRNAs, Table 3) were inserted in the pGreenPuro vector 
(SI505A-1, System Biosciences). The design of shRNAs targeting Tau or P53 was 
done following the manufacturer’s instructions or with the tool provided by Dr. 
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Hannon at http://katahdin.cshl.org//siRNA/RNAi.cgi?type=shRNA. Pseudo-lentiviral 
particles were produced in HEK-293 cells (HEK 293TN, System Biosciences) with 
the pPACKH1 kit (LV500A-1, System Biosciences) by the calcium phosphate 
transfection method85. Particles were harvested 48-72 h later, concentrated on a 30K 
MWCO Macrosep Advance Spin Filter (MAP030C37, Pall Corporation), aliquoted 
and stored at -80°C until use. Particle titers were determined at 72 h post-
transduction by calculating the percent of GFP-positive cells and the mean GFP 
intensity. Tau-KD and P53-KD cells were obtained upon transduction and selection in 
5 μg/mL puromycin for one to two weeks. 
Drug treatments  
Etoposide (100 mM stock in DMSO; ab120227, Abcam) treatment was followed by 
three washes with complete DMEM and cells were allowed to recover for the 
indicated times. The concentration of etoposide was adapted depending on the cell 
line, most treatments of SH-SY5Y cells were performed at 60 or 100 µM etoposide, 
whereas 15 µM etoposide was used for IMR5 cells and 30 µM etoposide for IMR32 
cells. When specified, recovery was done in the presence of 5 µg/mL nutlin-3 (5 
mg/mL stock in DMSO; SC-45061, Santa Cruz), 10 µg/mL of KU-55933 (10 mg/mL 
stock in DMSO; SML1109, Sigma-Aldrich), 10 µM MG132 (10 mM stock in DMSO, 
M7449, Sigma-Aldrich) or 25 µM cycloheximide (10 mg/ml stock in H2O, 01810, 
Sigma-Aldrich). Vehicle DMSO was added in the controls. 
Immune assays  
For immune staining, cells were grown on poly-D-lysine coated 8 well microscope 
slides (80826-IBI, Ibidi). Cells were fixed in paraformaldehyde and stained12 with 
primary antibodies 1 μg/mL Tau13 (sc-21796, Santa Cruz), 0.5 μg/mL pS129-H2A-X 
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(sc-517348, Santa Cruz), 0.13 μg/mL pS1981-ATM (#13050, Cell Signaling), 0.2 
μg/mL pT68-Chk2 (#2197, Cell Signaling), 0.4 μg/mL P53 DO-1 (sc-126, Santa 
Cruz,), 1 μg/mL pS15-P53 (ab223868, Abcam), 0.2 μg/mL MDM2 (#86934, Cell 
Signaling), 0.05 μg/mL clAsp175-Caspase3 (#9661, Cell Signaling), 0.5 μg/mL alpha-
tubulin (ab18251, Abcam). Detection of endogenous Tau entailed the testing of a 
number of commercial antibodies so to find the human-specific Tau13 monoclonal 
antibody against an amino-terminal epitope as reagent providing the most reliable 
detection of endogenous Tau. Although determination of DSBs by H2A-X is mostly 
performed by counting positive nuclear foci, we noticed that at the concentration of 
etoposide used here, single foci were poorly discernible, we nevertheless confirmed 
that mean intensity of nuclear H2A-X staining correlated with foci counting and 
decided to apply the first method for our quantifications of DNA damage. Detection 
by fluorescent laser confocal microscopy (Nikon C2 microscope) was done with 
2 μg/mL secondary antibodies anti-mouse IgG-Alexa594 or -Alexa 488 (A-11032, A-
11001, ThermoFisher Scientific) or anti-rabbit IgG-Alexa594 or -Alexa488 (A-11037, 
A-11034, ThermoFisher Scientific). Nuclei were counterstained with 0.5 μg/mL DAPI 
(D9542, Sigma-Aldrich). Images were usually taken with a line by line scan with a 
sequence of excitations, i.e. 405 nm laser with 464/40–700/100 nm emission filter, 
488 nm laser with 525/50 nm emission filter, and 561 nm laser with 561/LP nm 
emission filter. ImageJ was used for all image quantifications.  
For biochemical analysis by western blot, cells plated in 6 well plates were directly 
lysed in 40 µL SDS PAGE sample buffer (1.5% SDS, 8.3% glycerol, 0.005% 
bromophenol blue, 1.6% β-mercaptoethanol and 62.5 mM Tris pH 6.8) and incubated 
10 min at 100°C.For immune precipitation, cells from 10 cm plates were rinsed with 
PBS and collected by scraping and low speed centrifugation. Cell lysates were 
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prepared in 400 μL ice-cold RIPA buffer (R0278, Sigma-Aldrich), supplemented with 
protease and phosphatase inhibitor cocktails (S8820, 04906845001, Sigma-Aldrich) 
and treated with benzonase (707463, Novagen) 15 min at 37°C.  
Protein immune precipitation was performed by a batch procedure using Protein G-
Sepharose® beads (101241, Invitrogen) overnight at 4ºC with 40 µL 30% slurry 
beads and 1 µg of HT7 antibody (MN1000, Invitrogen) or P53 antibody (FL-393, bs-
8687R, Bioss Antibodies) antibody. The cell lysates for P53 immune precipitation 
were cleared by centrifugation at 20’000 g per 10 min. For immune blots12, we used 
0.2 μg/mL Tau13 (sc-21796, Santa Cruz), 0.18 μg/mL GAPDH (ab181602, Abcam), 
0.4 μg/mL P53 DO-1 (sc-126, Santa Cruz), 4 μg/mL P53 Pab 1801 (sc-98, Santa 
Cruz), 0.5 μg/mL pS15-P53 (ab223868, Abcam), 0.1 μg/mL rabbit D1V2Z MDM2 
(#86934, Cell Signaling), 0.2 μg/mL mouse SMP14 MDM2 (sc965, Santa Cruz), 0.05 
μg/mL clAsp175-Caspase3 (#9661, Cell Signaling), or 0.2 μg/mL p21 (sc53870, Santa 
Cruz). Immune precipitated Tau protein was detected with 0.1 μg/mL biotinylated 
HT7 antibody (MN1000B, ThermoFisher Scientific) and 0.2 μg/mL streptavidin-IRDye 
(926-32230, Licor Biosciences). In the co-IP experiments, the antibodies used were 
0.4 μg/mL P53 DO-1, 1 μg/mL Tau13 and 0.1 μg/mL D1V2Z MDM2. 
For in cell western, cells plated on poly-D-lysine-coated 96 well microtiter plates were 
fixed with cold 4% paraformaldehyde in PBS 15 min at 4°C, stained with 0.5 μg/mL 
pS129-H2A.X (sc-517348, Santa Cruz), anti-mouse IgG-IRDye680 (926-68070, Licor), 
and analyzed on a dual fluorescent scanner (Odyssey CLx, LICOR). Determination of 
0.5 ug/mL DAPI staining for normalization was performed with an absorbance reader 
(Infinite M Plex, Tecan). 
Cell death and senescence assays  
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The LDH (Pierce LDH Cytotoxicity Assay Kit; 88954, ThermoFisher Scientific) and 
MTS assay (CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay; G5421 
Promega) were done following the manufacturer’s instructions. For LDH, conditioned 
medium from cells plated in a 96 well microtiter plate was analyzed by measuring 
absorbance at 490 nm and 680 nm (Infinite M Plex, Tecan). Colorimetric measurement 
for MTS was performed at 490 nm (Infinite M Plex, Tecan). 
Senescence-associated β-galactosidase staining was determined on cells plated in 
6 well plates, fixed with 2% paraformaldehyde 10 min at RT and washed twice with 
gentle shaking 5 min at RT. Then, cells were incubated with 1 mg/mL X-gal (20 mg/mL 
stock in DMF; B4252, Sigma-Aldrich,) diluted in pre-warmed 5 mM potassium 
ferricyanide crystalline (P-8131, Sigma-Aldrich), 5 mM potassium ferricyanide 
trihydrate (P-3289, Sigma-Aldrich), and 2 mM magnesium chloride (M-8266, Sigma-
Aldrich) in PBS at pH 6.0. Acquisition and quantification of the images for SA-βGal and 
cell area was done with an automated live cell imager (Lionheart FX, BioTek). 
Comet assay  
The assay was performed according to the manufacturer’s instructions (STA-351, 
Cell Biolabs INC.). In short, cells were plated in 6 well plates for drug treatments, 
collected, counted, resuspended at 100,000 cells/mL and washed with PBS at 4°C. 
Cells were mixed at 1:10 with low melting agarose at 37°C, and poured on a glass 
microscope slide. After cell lysis, the slides were maintained at 4°C in alkaline buffer 
(pH >13) for 20 min. After electrophoresis, the slides were washed three times with a 
neutralizing buffer and stained with the Vista Green DNA Dye (#235003, Cell 
Biolabs). All manipulations were performed protected from direct light. Analysis was 
performed by capturing Z-stack images with a laser confocal microscopy and 
measurement of Olive tail moment with the CaspLab software.  
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RNA extraction and RT-qPCR  
Total RNA extraction using the TRIzol™ Reagent (15596026, Invitrogen) and 
cDNA synthesis using the GoScript™ Reverse Transcription Mix, Random Primers 
(A2800, Promega) were done according to the manufacturer’s instructions. 
Amplification was performed with SsoAdvanced™ Universal SYBR® Green 
Supermix (1725271, BioRad) with 43 cycles at 95 ̊C for 5 sec, 60 ̊C for 30 sec and 
60 ̊C for 1 min (for the primers see Table 2). Relative RNA expression was calculated 
using the comparative Ct method and normalized to the geometric mean of the 
GAPDH and HPRT1 mRNAs.  
Statistics and Reproducibility  
Statistical analysis was performed with the aid of GraphPad Prism version 8.4 
using the method specified in the legend of each figure. Exact p-values are specified 
in the figures. All quantifications were performed based on at least three independent 
biological replicates, sample size, number of replicates and how they are defined is 
specified in the figure legends. When indicated, western blots and microscopic 
images are shown for representative data.  
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Table 1: targeted gRNA sequences for human MAPT gene 
Oligo Sequence 
231 CACGCTGGGACGTACGGGTTGGG 
232 CCGCCAGGAGTTCGAAGTGATGGG 
Table 2: PCR Primers (all specific for homo sapiens mRNAs) 
Gene Forward primer (5'-3') Reverse primer (5'-3') 
MAPT GATCAGGATCCGTGAACTTTGAACC
AGGATGGC 
GATCAGGATCCGTGAACTTTGAACC
AGGATGGC 
MDM2 TGTTTGGCGTGCCAAGCTTCTC CACAGATGTACCTGAGTCCGATG 
TP53 CCTCAGCATCTTATCCGAGTGG TGGATGGTGGTACAGTCAGAGC 
CDKN1A AGGTGGACCTGGAGACTCTCAG TCCTCTTGGAGAAGATCAGCCG 
DDB2 CCAGTTTTACGCCTCCTCAATGG GGCTACTAGCAGACACATCCAG 
ZMAT3 GCTCTGTGATGCCTCCTTCAGT TTGACCCAGCTCTGAGGATTCC 
RRM2B ACTTCATCTCTCACATCTTAGCCT AAACAGCGAGCCTCTGGAACCT 
ASCC3 GATGGAAGCATCCATTCAGCCTA CCACCAAGGTTCTCCTACTGTC 
EI24 GCAAGTAGTGTCTTGGCACAGAG CAGAACACTCCACCATTCCAAGC 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
 
Table 3: Oligonucleotide annealed for shRNA sequences 
P53 
Sense 5’GATCCGACTCCAGTGGTAATCTACCTTCCTGTCAGAGTAGAT
TACCACTGGAGTCTTTTTG 3’ 
Antisense 3’CGACTCCAGTGGTAATCTACCTTCCTGTCAGAGTAGATTACC
ACTGGAGTCTTTTTGAATT 5’ 
Tau 
1881 
Sense 5’GATCCTGGTGAACCTCCAAAATCACTTCCTGTCAGATGATTT
TGGAGGTTCACCATTTTTG 3’ 
Antisense 3’CTGGTGAACCTCCAAAATCACTTCCTGTCAGATGATTTTGGA
GGTTCACCATTTTTGAATT 5’ 
Tau 
2112 
Sense 5’GATCCAACTGAGAACCTGAAGCACCAGCTTCCTGTCAGACTG
GTGCTTCAGGTTCTCAGTGTTTTTG 3’ 
Antisense 3’CAACTGAGAACCTGAAGCACCAGCTTCCTGTCAGACTGGTGC
TTCAGGTTCTCAGTGTTTTTGAATT 5’ 
Tau 
3127 
Sense 5’GATCCAGCAGACGATGTCAACCTTGTGCTTCCTGTCAGACAC
AAGGTTGACATCGTCTGCCTTTTTG 3’ 
Antisense 3’CAGCAGACGATGTCAACCTTGTGCTTCCTGTCAGACACAAGG
TTGACATCGTCTGCCTTTTTGAATT 5’ 
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Figure 1. Generation of Tau-KO and Tau-KD SH-SY5Y cells 
a. Scheme of the procedure used to generate CRISPR-Cas9 targeted cells and their 
characterization. Immune staining was performed with Tau13 antibody and nuclear 
staining with DAPI, western blot with Tau13 (loading control GAPDH) and immune 
precipitation & western blot with HT7 antibody, parental cells (wt) served as control. 
Amino acid sequences of the first MAPT coding exon in all lines demonstrate 
successful CRISPR-Cas9-editing causing frameshift (underlined in italics) into early 
stop codons (asterisks) for both alleles of 232P and 231K cells. b. Scheme of 
procedure used to generate Tau-KD cell lines and for their characterization by 
immune staining and western blot for Tau expression when compared to parental 
cells (wt) or cells transfected with the parental shRNA plasmid (ctrl). Scale bar 50 
µm. 
Figure 2. Tau deficiency confers resistance to etoposide-induced apoptosis 
Scheme representing the design of the experiment with parental and 231A (Tau) 
cells compared to 232P and 231K (Tau-KO) cells treated 30 min with 60 M 
etoposide and recovered as indicated before analysis. LDH and MTS values are 
shown as percentage of parental cells (wt), mean ± SD of 5 biological replicates. To 
measure activation of apoptosis, percent positive cells for cleaved-caspase-3 
(clCasp3) is determined on confocal microscope images and normalized for total 
DAPI-positive cells, mean ± SD of 5 images for the untreated cells (ctrl) and of 15 
images for etoposide-treated cells (60 M eto), n >500 cells/condition, representative 
experiment of n>3 biological replicates. Activated clCasp3 was also analyzed by 
western blot with GAPDH as loading control and 15 and 17 kDa clCasp3 quantified 
by normalization with GAPDH, mean +/- SD (n = 3 biological triplicates). Statistical 
analysis by independent measures ordinary 2way ANOVA, source of variation for cell 
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lines (in bold), multiple Bonferroni pairwise comparisons for treatment between lines 
(in italics) or for each line (in vertical). 
Figure 3. Tau depletion increases cellular senescence 
a. Scheme of the procedure followed to assess cellular senescence upon 30 min 
treatment with 60 M etoposide followed by 3 d recovery. b. Quantification of p21 
amount in cell lysates by western blot in parental (wt) or 232P (Tau-KO) cells under 
control conditions (ctrl) or following etoposide treatment (60 µM eto) normalized for 
GAPDH, mean +/- SD of 3 biological replicates. Quantification of mean cell area and 
percent positive cells for senescence-associated β-galactosidase (SA- βGal) 
determined with a high-content microscope scanner, mean ± sem of 4 (Tau-KO cells) 
or 3 (Tau-KD) independent experiments, n >8000 cells. Data are shown as fold of wt 
cells at basal conditions c. Same as in b. for mock shRNA (ctrl) or Tau 3127 shRNA 
(Tau-KD) cells. d. Representative images of SA-βGal staining (in blue), bright-field, 
scale bar = 100 m. Statistical analysis by independent measures ordinary 2way 
ANOVA, source of variation for cell lines (in bold), multiple Bonferroni pairwise 
comparisons for treatment between lines (in italics) or for each line (in vertical).  
Figure 4. Reduced P53 in Tau-KO cells is not caused by DDR activation 
For all panels, parental (wt) or 232P (Tau-KO) cells were treated 30 min with the 
indicated etoposide concentrations and recovery times. a. Mean intensity +/- SD of 
H2A-X staining normalized for DAPI staining by in-cell western is shown as fold of 
wt cells at basal conditions, n = 5 of biological replicates in a 96 well plate. Non-
parametric independent Mann-Whitney U test between lines (in bold), or for each 
dose between lines (in italics). b. Olive moment in the Comet assay is shown as 
mean +/- sem, n = 84-146 cells/condition. c. and d. Mean intensity ± sem of single 
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cell nuclear H2A-X, pATM or pChk2 staining (DAPI mask, ImageJ) is shown as fold 
of wt cells at basal conditions, n >100 cells/condition distributed over 5 images. 
Statistical analysis by independent measures ordinary 2way ANOVA, source of 
variation for cell lines (in bold), multiple Bonferroni pairwise comparisons of each 
condition between lines (in italics) and of time points for each line (b and d, in 
vertical).  
Figure 5. Tau depletion decreases P53 level and apoptosis 
For all panels the indicated cell lines (Tau-KO are 232P cells) were treated 30 min 
with the indicated etoposide concentrations and recovery times. a. Mean intensity +/- 
sem of single cell nuclear P53 staining (DAPI mask, ImageJ) is shown as fold of wt 
cells at basal conditions, n >100 cells/condition distributed over 5 images. b. Percent 
clCasp3-positive cells are shown as mean ± SD of 5 images for the untreated cells 
and of 15 images for etoposide-treated cells, n >500 cells/condition. c. Mean intensity 
+/- sem of single cell Tau staining (tubulin mask, ImageJ) for the indicated cell lines is 
shown as percent of mock shRNA cells (ctrl), n >160 cells/condition distributed over 5 
images. d. Mean intensity of single cell nuclear P53 staining quantified as in a., n 
>380 cell/condition distributed over 15 images from n = 3 biological replicates. e. 
Percent clCasp3-positive cells quantified as in b., n >500 cell/condition. f. An 
arbitrary threshold was applied in order to count P53-positive cells as percentage +/- 
SD of total DAPI-positive cell number, n >100 cells/conditions. For the comparison 
between the four cell lines (a), non-parametric independent Mann Whitney U test for 
genotype (in bold) and Kruskal-Wallis pairwise comparison of treatment for cell lines 
with same genotype (in italics) or for each line (in vertical).For the dose-dependency 
(a and b), non-parametric independent Mann Whitney U test between cell lines (in 
bold), Kruskal-Wallis pairwise comparison for each dose (in italics) and between 
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doses (in vertical). Non-parametric independent Mann Whitney U test (c – e) 
between control and the three Tau-KD lines (in bold) and Kruskal-Wallis pairwise 
comparison for each Tau-KD line (in italic) and for each treatment (in vertical). 
Unpaired two-tailed t test with Welch’s correction (f). 
Figure 6. Differential regulation of P53 transcription targets 
Extracted RNA from parental (wt) and 232P (Tau-KO) cells in a. or from control 
shRNA plasmid (ctrl )  and 3127 (Tau-KD) cells in b. at basal conditions or after 30 
min 60 M etoposide and 6 h recovery, was subjected to reverse-transcription and 
qPCR with primers specific for the indicated transcripts. Mean +/- SD of relative 
mRNA levels (n = 3) shown as fold of the respective basal conditions for parental or 
control cells. Statistical analysis by independent measures ordinary 2way ANOVA, 
source of variation for cell lines (horizontal), multiple Sidak pairwise comparisons for 
treatment for each line (in vertical).   
Figure 7. Role of P53 and MDM2 modifications for P53 function and stability 
a. and b. Parental (wt) or 232P (Tau-KO) cells treated 30 min without (basal) or with 
60 M etoposide and recovered for 6 h in the absence (eto) or presence of 10 µg/mL 
KU-55933 and/or 5 µg/mL nutlin-3. a. Mean intensity ± sem of single cell nuclear P53 
or MDM2 (DAPI mask, ImageJ) shown as fold of basal conditions, n >100 
cells/condition distributed over 5 images. b. Percent clCasp3-positive cells shown as 
mean ± SD of 5 images (basal) or 15 images (treatments), n >500 cells/condition. 
Non-parametric independent samples test and Kruskal-Wallis pairwise comparison 
between cell lines (in bold) or for treatment for each cell line (in vertical)c. Western 
bot analysis of P53 in parental (wt) or 232P (Tau-KO) cells at basal conditions, after 
30 min 60 M etoposide and 4 h recovery without or with 10 M MG132. GAPDH 
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served as loading control. d. Parental (wt) or 232P (Tau-KO) cells pre-treated for 30 
min with 60 M etoposide followed by 4 h with 10 M MG132, were incubated with 25 
M of cycloheximide (CHX) for the indicated chase times. Single cell nuclear P53 or 
nuclear MDM2 (DAPI mask, ImageJ) shown as fold of wt cells at basal conditions. 
Mean intensity ± sem of n >100 cells/condition distributed over 5 images. 
Independent measures ordinary 2way ANOVA, source of variation for cell lines 
(bold), multiple Bonferroni pairwise comparisons of treatment for each line (in italic). 
e. Parental (wt) or (Tau-KO) 232P cells treated for 30 min with 60 M etoposide and 
6 h recovery analyzed with a 90 kDa MDM2 rabbit antibody (green and middle panel 
with GAPDH as loading control) or a 60 & 90 kDa MDM2 mouse antibody (red and 
bottom panel).  
Fig.8 Tau does not directly interact with P53 
Cell lysates of SH-SY5Y treated with 10 M of MG132 to stabilize P53 expression, 
without (ctrl) or with (eto) a 30 min pre-treatment with 60 M etoposide, were 
subjected to immune precipitation of endogenous P53 with a rabbit antibody (P53) or 
with a rabbit GFP antibody as negative IP control (GFP). Western blot analysis for 
co-precipitation of MDM2 or Tau with the respective mouse antibodies as indicated. 
The blots on the top show the analysis of the starting material (cell lysates), those on 
the bottom the immunoprecipitation (IP). The P53 blots are entirely shown, whereas 
for MDM2 and Tau, the blots were cut between the 55 kDa and the 95 kDa protein 
size markers and analyzed separately. 
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Supplementary Figure 1. DSBs-induced apoptosis is P53-dependent in SH-SY5Y 
cells. a. Scheme of procedure used to generate P53-KD cells and for their 
characterization by western blot and P53 immune staining when compared to cells 
transduced with the parental shRNA plasmid (ctrl). b. Cells at basal conditions (ctrl) or 
treated 30 min with 60 M etoposide and recovered for 6 h before western blot analysis 
with the indicated P53 antibodies. GAPDH served as loading control. c. Western blot 
quantification of P53 signal intensity normalized for GAPDH shown as fold of control cells 
at basal conditions, mean +/- SD of n = 3 biological replicates. On the left is show the 
quantification of P53 immune staining as fold of control cells at basal conditions, mean 
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intensity +/- sem of single cell nuclear P53 staining (DAPI mask, ImageJ), n >219 
cells/condition distributed over 5 images. d. Quantification of clCasp3 immune staining 
shown as percent of total DAPI-positive cells, mean ± SD of 5 images for the untreated 
cells (ctrl) and of 15 images for etoposide-treated cells (60 µM eto), n >500 cells/condition. 
Statistical analysis by independent measures ordinary 2way ANOVA, source of variation 
for cell lines (in bold), multiple Bonferroni pairwise comparisons among lines for each 
treatment (in italics), or among treatment for each line (in vertical). 
 
Supplementary Figure 2. Tau deficiency reduces cellular P53. a. Representative laser 
confocal microscopy images of P53 DO-1 antibody-immune stained parental cells (wt) and 
the indicated CRISPR-Cas9 cell lines at basal conditions (control) or treated for 30 min 
with 60 M etoposide and recovered for 6 h. Shown are also the nuclear staining with 
DAPI. Scale bar 50 µm. Quantification of mean intensity +/- sem of single cell nuclear P53 
staining (DAPI mask, ImageJ) shown as fold of wt cells at basal conditions using the 
indicated P53 antibodies, n >90 cells/condition distributed over 5 images. b. Parental (wt) 
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or 232P (Tau-KO) cells at basal conditions (ctrl) or treated for 30 min with 60 M etoposide 
followed by 6 h recovery were analyzed for P53 by western blot with the indicated P53 
antibodies, n = 3 biological replicates. GAPDH served as loading control. Quantification of 
P53 signal intensity normalized for GAPDH, mean +/- SD shown as fold of control (wt or 
ctrl cells at basal conditions). Statistical analysis by independent measures ordinary 2way 
ANOVA, source of variation for cell lines (in bold), multiple Bonferroni pairwise 
comparisons for each treatment among lines (in italics), or among treatment for each line 
(in vertical). 
Supplementary Figure 3. Restoring Tau expression in Tau-KO cells rescues P53 and 
the apoptotic phenotype. a. Parental (wt), 232P (KO cells) or 232P cells stably re-
expressing 4R-Tau (Tau441) analyzed by western blot with the Tau13 antibody. b. 
Quantification of single cell nuclear P53 immune staining (DAPI mask, Image J) of 232P 
Tau-KO cells or 232P-Tau441 cells at basal conditions (ctrl) or treated 30 min with 60 M 
etoposide and allowed to recover 6 h (60 M eto), mean ± sem of n >100 cells/condition 
distributed over 5 images shown as fold of 232P cells at basal conditions. c. LDH release 
from the same cells treated as in b. (2 d recovery). Values are shown as percentage of 
Tau-KO cells at basal conditions, mean ± SD of 12 wells from three independent 
experiments. Cells were also analyzed by immune staining for clCasp3 at 6 h recovery. 
Percent clCasp3-positive cells, mean ± SD of 10 images, n >500 cells/condition. d. 
Quantification of Tau13 immune stained Tau in parental cells (endogenous Tau, wt), or in 
GFP-positive 232P cells (KO cells) transiently transfected with a 1:10 ratio of empty:GFP 
plasmids (GFP) or of 3R-Tau:GFP plasmids (Tau410). Cells were stained 3 days after 
transfection (GFP mask, Image J). e. Immune staining quantification of nuclear P53 (DAPI 
mask, Image J) in GFP-positive 232 cells (KO cells) transiently transfected as in d. and 
treated for 30 min with 60 M etoposide and recovered for 6 h, mean intensity ± sem 
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shown as fold of control-transfected 232P cells, n >100 cells/condition distributed over 5 
images. Statistical analysis by independent measures ordinary 2way ANOVA, source of 
variation between non-transfected and Tau-transfected conditions (in bold), multiple 
Bonferroni pairwise comparisons among lines for each treatment (in italics), among 
treatment for each line (b and c, in vertical). 
Supplementary Figure 4. Reduced etoposide-induced P53 protein in Tau-KD IMR5 
and IMR32 cells. a. Cell lysates obtained from IMR5 cells transduced with the parental 
shRNA plasmid (ctrl) or with the Tau shRNA plasmid 2112 (Tau-KD) were analyzed by 
western blot for Tau expression. The Tau signal was normalized for GAPDH and reported 
as percent of the control, mean +/- SD, n = 3 biological replicates. Unpaired student t-test. 
b. The two IMR5 cell lines at basal conditions or treated 30 min with 15 M etoposide and 
recovered for 6 h were analyzed by western blot with the P53 DO-1 antibody. The Tau 
signal was normalized for GAPDH and reported as fold of the control, mean +/- SD, n = 3 
biological replicates. Same conditions were applied to quantify immune stained P53, mean 
intensity +/- sem of single cell nuclear P53 staining (DAPI mask, ImageJ) shown as fold of 
untreated control cells (ctrl), n >100 cells/condition distributed over 5 images. c. Apoptotic 
cells were determined by clCasp3 immune staining and reported as percent clCasp3-
positive cells of total DAPI-positive cells, mean ± SD of 5 images for the untreated cells 
(ctrl) and of 15 images for etoposide-treated cells (15 M eto), n >500 cells/condition. d.  
Same as in a. for IMR32 cells transduced with the parental shRNA plasmid (ctrl) or with 
Tau shRNA plasmid 3127 (Tau-KD). e. Same as in b. for the western blot analysis. f. 
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Same as in c. for 15 and 17 kDa clCasp3 fragments determined by western blot, mean +/- 
SD (n = 3 biological triplicates). Statistical analysis by independent measures ordinary 
2way ANOVA, source of variation for cell lines (in bold), multiple Bonferroni pairwise 
comparisons for treatment between lines (in italics) or for each line (in vertical). 
Supplementary Figure 5. Tau deficiency affects MDM2. a. Representative images by 
laser confocal microscopy of parental (wt) or CRISPR-Cas9 cell lines immune stained with 
the rabbit MDM2 antibody and counter-stained with DAPI. Cells at basal conditions 
(control) or after 30 min 60 M etoposide and 6 h recovery, scale bar 50 µm. Mean 
intensity +/- sem of single cell nuclear MDM2 staining (DAPI mask, ImageJ) shown as fold 
of wt cells at basal conditions, n >90 cells/condition distributed over 5 images. Statistical 
analysis by independent measures ordinary 2way ANOVA, source of variation for 
genotype (in bold), multiple Bonferroni pairwise comparisons for etoposide treatment 
between lines with same genotype (in italics) or for the etoposide treatment for each line 
(in vertical). 
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Supplementary Figure 6. Analysis of pS15-P53 phosphorylation. a. Parental (wt) or 
232P (Tau-KO) cells at basal conditions or after 30 min 60 M etoposide and 6 h recovery 
were analyzed for pS15-P53 or P53 by western blot, n = 3 biological triplicates. 
Quantification was performed by measuring the signal intensity of pS15-P53 normalized for 
the signal of total P53, mean +/- SD shown as percent of control (parental cells at basal 
conditions). Statistical analysis by independent measures ordinary 2way ANOVA, source 
of variation for cell lines (in bold), multiple Bonferroni pairwise comparisons among lines 
for each treatment (in italics), or of treatment for each line (in vertical). b. Parental (wt) or 
232P (Tau-KO) cells at basal conditions (ctrl) or analyzed after 6 h recovery from a 30 min 
treatment in the absence or presence of 60 M etoposide in the absence (eto), the 
recovery was performed in the absence or presence of 5 µg/mL nutlin-3 (eto nut) or 10 
µg/mL KU-55933 (eto KU) as indicated. Analysis by western blot for pS15-P53 or P53, a 
representative experiment out of three experiments is shown.  
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Supplementary Figure 7. Unprocessed western blot images (in grey tones) used for 
creating the corresponding panels in Fig.1a and 1b. Shown are also the original dual 
fluorescence images. 
 
Supplementary Figure 8. Unprocessed western blot images (in grey tones) used for 
creating the corresponding panels in Fig.2. Shown are also the original dual fluorescence 
image. 
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Supplementary Figure 9. Unprocessed western blot images used for creating the 
corresponding panels in Fig.7c and 7e.  
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Supplementary Figure 10. Unprocessed western blot images used for creating the 
corresponding panels in Fig.8. The MDM2 and Tau blots shown on the left were cut 
between the 55 kDa and the 95 kDa protein size markers and analyzed separately. 
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Supplementary Figure 11. Unprocessed gel image used for creating Supplementary 
Fig.3a. 
 
